GDF15 and myeloid sarcoma: Although specific longitudinal studies on GDF-15 modulation by second-line therapies in MS remain limited, elevated CSF GDF-15 levels have consistently been associated with progressive MS phenotypes, likely reflecting chronic neuroinflammation and mitochondrial stress [21].